Nothing Special   »   [go: up one dir, main page]

ES2146228T3 - Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos. - Google Patents

Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos.

Info

Publication number
ES2146228T3
ES2146228T3 ES93906193T ES93906193T ES2146228T3 ES 2146228 T3 ES2146228 T3 ES 2146228T3 ES 93906193 T ES93906193 T ES 93906193T ES 93906193 T ES93906193 T ES 93906193T ES 2146228 T3 ES2146228 T3 ES 2146228T3
Authority
ES
Spain
Prior art keywords
epiandrosterone
dehydro
analogs
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906193T
Other languages
English (en)
Inventor
Jonathan W Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University filed Critical East Carolina University
Application granted granted Critical
Publication of ES2146228T3 publication Critical patent/ES2146228T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PRESENTA UN METODO PARA COMBATIR EL CANCER DE UN SUJETO QUE CONSISTE EN ADMINISTRAR A DICHO SUJETO DESHIDROEPIANDROSTERONA (DHEA) O UN ANALOGO DE LA MISMA EN UNA CANTIDAD EFECTIVA COMO PARA COMBATIR EL CANCER SEGUN EL CUAL LOS COLAPSOS INDUCIDOS POR LA DHEA O EL ANALOGO DE LA MISMA SE COMBATEN ADMINISTRANDO AL SUJETO UNA UBIQUINONA, EN UNA CANTIDAD EFECTIVA COMO PARA COMBATIR EL COLAPSO INDUCIDO POR LA DHEA O EL ANALOGO DE LA MISMA. UN ANALOGO DE LA DHEA PREFERENTE PARA LLEVAR A CABO EL METODO DE LA INVENCION ES LA 16 ALFA-FLUOREPIANDROSTERONA Y UNA UBIQUINONA PREFERENTE PARA LLEVAR A CABO EL METODO DE LA INVENCION ES LA COENZIMA Q10.
ES93906193T 1992-02-24 1993-02-23 Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos. Expired - Lifetime ES2146228T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84051092A 1992-02-24 1992-02-24

Publications (1)

Publication Number Publication Date
ES2146228T3 true ES2146228T3 (es) 2000-08-01

Family

ID=25282563

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906193T Expired - Lifetime ES2146228T3 (es) 1992-02-24 1993-02-23 Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos.

Country Status (9)

Country Link
US (1) US5527789A (es)
EP (1) EP0627921B1 (es)
JP (1) JPH07504198A (es)
AT (1) ATE193447T1 (es)
AU (1) AU676470B2 (es)
CA (1) CA2117532C (es)
DE (1) DE69328771T2 (es)
ES (1) ES2146228T3 (es)
WO (1) WO1993016704A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US7893044B2 (en) 1995-02-24 2011-02-22 Epigenesis Pharmaceutical, Inc. Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
EP1083904A2 (en) 1998-06-11 2001-03-21 Endorecherche Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
EP1955700B9 (en) 1999-09-30 2011-09-07 Harbor BioSciences, Inc. Therapeutic treatment of androgen receptor driven conditions
WO2001062259A1 (en) 2000-02-25 2001-08-30 Hollis Eden Pharmaceuticals Method of treatment of prostate cancer
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
CN1681520A (zh) * 2002-06-17 2005-10-12 埃匹吉尼斯医药有限公司 脱氢表雄酮的喷雾剂和采用其组合物治疗哮喘或慢性阻塞性肺部疾病的方法
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
KR101372783B1 (ko) 2004-01-22 2014-03-11 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
AU2008228764B2 (en) 2007-03-22 2014-05-08 Berg Llc Topical formulations having enhanced bioavailability
BRPI0911658A2 (pt) 2008-04-11 2015-10-13 Cytotech Labs Llc métodos e usos de indução de apoptose em células de câncer
US20140024022A1 (en) * 2009-02-09 2014-01-23 Nihon Kohden Corporation Cell treatment solution and method of preparing stained cell suspension for a measurement of nuclear dna by flow cytometry
KR20120088555A (ko) 2009-05-11 2012-08-08 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자, 다차원 세포내 분자 또는 환경적 영향인자를 사용한 대사적 장애의 진단 방법
EP2544663B1 (en) 2010-03-12 2018-01-03 Berg LLC Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
MX369543B (es) 2011-06-17 2019-11-12 Berg Llc Composiciones farmaceuticas inhalables.
US20130064815A1 (en) * 2011-09-12 2013-03-14 The Trustees Of Princeton University Inducing apoptosis in quiescent cells
EP2983654A4 (en) 2013-04-08 2016-11-30 Berg Llc TREATMENT OF CANCER USING COENZYME POLYTHERAPIES Q10
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
TW201831436A (zh) * 2017-02-24 2018-09-01 郭盈妤 分離自牛樟芝的化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5001119A (en) * 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
CA2066716A1 (en) * 1989-09-25 1991-03-26 Raymond A. Daynes Use of steroid hormones in compositions for inducing t cell lymphokine production
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
IE900306A1 (en) * 1990-01-29 1991-07-31 Elan Corp Agent for use in the prevention, control or reversal of¹hypertension

Also Published As

Publication number Publication date
WO1993016704A1 (en) 1993-09-02
EP0627921A4 (en) 1995-03-01
CA2117532C (en) 2001-04-10
ATE193447T1 (de) 2000-06-15
EP0627921B1 (en) 2000-05-31
US5527789A (en) 1996-06-18
AU676470B2 (en) 1997-03-13
CA2117532A1 (en) 1993-09-02
AU3731793A (en) 1993-09-13
DE69328771T2 (de) 2000-12-07
EP0627921A1 (en) 1994-12-14
DE69328771D1 (de) 2000-07-06
JPH07504198A (ja) 1995-05-11

Similar Documents

Publication Publication Date Title
ES2146228T3 (es) Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos.
ES2058799T3 (es) Composiciones estabilizadas que contienen factor de crecimiento epidermico.
ES2045110T3 (es) Mejoras en o relacionadas con antagonistas de leucotrienos.
ES2052881T3 (es) Agentes reductores de la presion sanguinea.
ES2071989T3 (es) Analogos de oligonucleotidos.
ES2184929T3 (es) Mezclas de organo-polisulfanos y procedimiento para la preparacion de mezclas de caucho que los contienen.
ES2059571T3 (es) Fumagilina como agente angiostatico.
ES2079063T3 (es) Utilizacion de analogos de vitamina d en el tratamiento del acne.
ES2033426T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.
ES2089301T3 (es) Formulaciones analogas de lh-rh.
ES2113127T3 (es) Derivado de androstenona.
ES2147238T3 (es) Nuevos analogos estructurales de la vitamina d.
MX9305769A (es) Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
ES2136725T3 (es) Utilizacion de 2-amino-6-n-propil-amino-4,5,6,7-tetrahidrobenzotiazol (pramipexol) como medicamento con efecto antidepresivo.
ES2192668T3 (es) Compuestos biciclicos-aromaticos.
IL64292A0 (en) D-homosteroids,their manufacture and pharmaceutical compositions containing them
AR002909A1 (es) Composicion fungicida y procedimiento para combatir hongos fitopatogenos.
ES2092981T3 (es) Derivados de aristeromicina/adenosina.
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
IT8619242A0 (it) Scarpone da sci del tipo ad ingresso dal retro.
ES2159357T3 (es) Derivados terpenoides (sarcodictinas) utiles como agentes antitumorales.
ES2094522T3 (es) Utilizacion de la creatinina fosfato o del acido fosfoenol piruvico para el tratamiento de los tumores.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 627921

Country of ref document: ES